# CJC-1295 References: The Cited Research Record

> The full CJC-1295 reference list — every study cited across this review, with authors, journals, DOIs, and PubMed links: Teichman 2006, Jette 2005, Ionescu/Frohman 2006, Alba 2006, and more.

Every quantitative claim on this site resolves to one of the studies below. Authors, journal, year, DOI, and PubMed link for each — the source state behind every figure.

## How this reference list works

This is the source state for the entire CJC-1295 review. Each inline [N] marker on the research, pharmacokinetics, DAC-vs-no-DAC, dosage, and FAQ pages corresponds to a numbered entry here. The human pharmacokinetic core rests on three studies — Teichman 2006 [1], Jette 2005 [2], and Ionescu and Frohman 2006 [3] — supported by the mouse growth study [4], the proteomic biomarker work [5], the GHRH-degradation and substitution chemistry [7][8], and the analytical and review literature [6][13][14][15].

Where a registry value is contested — the molecular formula and CAS attribution for the DAC variant differ across chemical-supplier sources — this review flags the disagreement rather than asserting a single figure. The full reference list below is the record this site is built on; nothing on the site makes a quantitative claim that is not traceable to one of these entries.

## References

[1] Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. https://pubmed.ncbi.nlm.nih.gov/16352683/
[2] Jette L, Leger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. https://pubmed.ncbi.nlm.nih.gov/15817669/
[3] Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-4797. https://pubmed.ncbi.nlm.nih.gov/17018654/
[4] Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1294. https://pubmed.ncbi.nlm.nih.gov/16822960/
[5] Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res. 2009;19(6):471-477. https://pubmed.ncbi.nlm.nih.gov/19386527/
[6] Henninge J, Pepaj M, Hullstein I, Hemmersbach P. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Test Anal. 2010;2(11-12):647-650. https://doi.org/10.1002/dta.233
[7] Incorporation of D-Ala2 in growth hormone-releasing hormone-(1-29)-NH2 increases the half-life and potency (D-Ala2 GHRH analog study). 1994. https://pubmed.ncbi.nlm.nih.gov/7962295/
[8] Frohman LA, Downs TR, Heimer EP, Felix AM. Dipeptidylpeptidase IV and trypsin-like enzymatic degradation of human growth hormone-releasing hormone in plasma. J Clin Invest. 1989;83(5):1533-1540. https://pubmed.ncbi.nlm.nih.gov/2565342/
[9] Modified GRF (1-29): tetrasubstituted hGRF(1-29) without the DAC albumin-binding moiety; short-acting no-DAC form. Reference overview. https://en.wikipedia.org/wiki/Modified_GRF_(1-29)
[10] Pharmacokinetics of growth hormone releasing factor [GRF(1-29)NH2] in normal men (GRF 1-29 pharmacokinetics study). 1986. https://pubmed.ncbi.nlm.nih.gov/?term=pharmacokinetics+GRF+1-29+NH2+normal+men
[11] Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide (ipamorelin PK-PD study). Pharm Res. 1999. https://pubmed.ncbi.nlm.nih.gov/10496658/
[12] PEGylation of growth hormone-releasing hormone (GRF) analogues. Adv Drug Deliv Rev. 2003. https://pubmed.ncbi.nlm.nih.gov/14499707/
[13] Granata R, Leone S, Zhang X, Gesmundo I, et al. Growth hormone-releasing hormone and its analogues in health and disease. Nat Rev Endocrinol. 2025;21(3):180-195. https://pubmed.ncbi.nlm.nih.gov/39537825/
[14] Advances in the detection of growth hormone releasing hormone synthetic analogs (GHRH-analog detection review). Drug Test Anal. 2021. https://pubmed.ncbi.nlm.nih.gov/34665524/
[15] Qualitative identification of growth hormone-releasing hormones in human plasma by means of immunoaffinity purification and LC-MS (immunoaffinity GHRH-MS study). Anal Bioanal Chem. 2016. https://pubmed.ncbi.nlm.nih.gov/26879649/

---

The CJC-1295 record read as a state machine — each figure logged to its study and tagged confirmed, the absent long-term human safety data left in plain view as the loudest state on the panel; no clinic behind the interface and nothing here dispensed or sold.